This article is more than 5 years old. Information may no longer be current.

Net losses increase for InSite in first quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ALAMEDA, Calif. – InSite Vision reported a first quarter loss in 2006 of $5.3 million, increased from net losses of $3.5 million during the first quarter in 2005, the company said in a news release.

The company said its research and development expenses had increased during the quarter as the company readies AzaSite (1% azithromycin solution in DuraSite) for regulatory filing and approval. Results from a phase 3 trial showed AzaSite had a significantly higher clinical resolution rate than patients on vehicle.

InSite markets the OcuGene glaucoma genetic test for disease management.